EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review

Florine Leipp iD, Jérôme Vialaret, Pablo Mohaupt, Salomé Coppens, Aurore Jaffuel, Ann-Christin Niehoff, Sylvain Lehmann iD, Christophe Hirtz

Brain Communications · 30.10.2024 · 6 (6)

DOI: 10.1093/braincomms/fcae396 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Communications, online erschienen am 07.11.2024. Verfasst von Florine Leipp und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shimadzu France SAS France, Noisiel, France. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shimadzu Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Astrocytes are fundamental in neural functioning and homeostasis in the central nervous system. These cells respond to injuries and pathological conditions through astrogliosis, a reactive process associated with neurodegenerative diseases such as Alzheimer’s disease. This process is thought to begin in the early stages of these conditions. Glial fibrillary acidic protein (GFAP), a type III intermediate filament protein predominantly expressed in astrocytes, has emerged as a key biomarker for monitoring this response. During astrogliosis, GFAP is released into biofluids, making it a candidate for non-invasive diagnosis and tracking of neurodegenerative diseases. Growing evidence positions GFAP as a biomarker for Alzheimer’s disease with specificity and disease-correlation characteristics comparable to established clinical markers, such as Aβ peptides and phosphorylated tau protein. To improve diagnostic accuracy, particularly in the presence of confounders and comorbidities, incorporating a panel of biomarkers may be advantageous. This review will explore the potential of GFAP within such a panel, examining its role in early diagnosis, disease progression monitoring and its integration into clinical practice for Alzheimer’s disease management.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseastrocytesbiomarkerglial fibrillary acidic proteinreactive astrogliosis

Autor:innen und Institutionen

  • Shimadzu France SAS France, Noisiel, France.
  • IRMB-PPC, INM, Univ Montpellier, CHU Montpellier, INSERM CNRS, Montpellier, France.
  • Shimadzu Europa GmbH, Duisburg, Germany.

ORCID-Profile: Florine Leipp, Sylvain Lehmann

Förderung

  • Shimadzu Corporation

Zitieren

APA

Leipp, F., Vialaret, J., Mohaupt, P., Coppens, S., Jaffuel, A., Niehoff, A. C., Lehmann, S., & Hirtz, C. (2024). Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review. Brain Communications, 6(6). https://doi.org/10.1093/braincomms/fcae396

Vancouver

Leipp F, Vialaret J, Mohaupt P, Coppens S, Jaffuel A, Niehoff AC, et al. Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review. Brain Communications. 2024;6(6). doi:10.1093/braincomms/fcae396

BibTeX
@article{Leipp2024,
  author = {Leipp, Florine and Vialaret, Jérôme and Mohaupt, Pablo and Coppens, Salomé and Jaffuel, Aurore and Niehoff, Ann-Christin and Lehmann, Sylvain and Hirtz, Christophe},
  title = {Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review},
  journal = {Brain Communications},
  year = {2024},
  volume = {6},
  number = {6},
  doi = {10.1093/braincomms/fcae396}
}
Kostenlos starten →